
Happy #Postdoctober! Meet Mia MacDonald, a Surgical Oncologists As Scientists (SOAS) research fellow at #UCSDSurgery who researches therapies for mucus-producing cancer in the appendix in the lab of Andrew Lowy, MD. #UCSDSurgery #SurgicalScience
✓Professor of Surgery & Pharmacology at UC San Diego. Surgical Oncologist. Surgeon-Scientist. Exec VC of Research. “Views expressed are my own personal beliefs”

Happy #Postdoctober! Meet Mia MacDonald, a Surgical Oncologists As Scientists (SOAS) research fellow at #UCSDSurgery who researches therapies for mucus-producing cancer in the appendix in the lab of Andrew Lowy, MD. #UCSDSurgery #SurgicalScience

🚨⭐️HOT OFF THE PRESS👉Pleased to share our new paper, led by the amazing @JulianaRBeal @niamhjcoleman @JiaJennyLiu 👉Precision before incision: neoadjuvant tumor-agnostic therapies.” 👉Nine tumor-agnostic drugs now have a case for earlier use, before resistance sets in and with organ preservation in mind. 👉A PD-1 blockade hit a 100% complete response in MMR-deficient rectal cancer. 🧬 @JasonSicklick @OncoAlert @oncodaily cell.com/trends/cancer/abstr… #PrecisionOncology

11 surgeons in our department were named "Top Docs" in the annual @SanDiegoMag "Physicians of Exceptional Excellence" survey. Congratulations to our 2026 Top Docs! #UCSDSurgery #TopDocs health.ucsd.edu/top-doctors/

Moores Cancer Center at UC San Diego Health has transformed its clinical trials enterprise, becoming a leader in innovative clinical trial design. STRIPe (STudy of Real-world Individualized Precision-oncology) is a powerful example of this progress — the first randomized precision oncology trial of its kind, testing personalized, molecularly matched treatment strategies against standard-of-care therapy for patients with advanced cancers. Learn more: bit.ly/4rKmGWG

@wmehtsun, MD, MPH, @nickneel8, MD, and team used a national database of more than 1.2 million patients to show that a simple imaging technique used during gallbladder surgery may significantly improve patient safety. Read the manuscript in @JAMASurgery: jamanetwork.com/journals/jam…

For the first time, two teleoperated humanoid robots have been used to complete two surgeries during a preclinical trial. #UCSDSurgery faculty and trainees played key research and clinical roles in this effort. Read the story: today.ucsd.edu/story/surgeon…

July 13 is National GIST Awareness Day. "Our work is focused on understanding the biology and translating those discoveries into new treatment options." — Jason Sicklick, MD Learn about Sicklick's role in #GIST treatment: health.ucsd.edu/news/feature…

A 4-line standard has held for 6 years in advanced GIST. Now PEAK phase 3 data on bezuclastinib plus sunitinib is changing the conversation: PFS 16.5 vs 9.2 months (HR 0.50, P<.0001) and ORR nearly doubled. Sarcoma experts break down what comes next. Watch the full episodes: hubs.li/Q04mnH2t0 (hubs.li/Q04mnCg50) @JasonSicklick @UCSDsurgery @AgulnikMd @CityofHope @NeetaSomaiahMD @UTMDAnderson @immunosarc @NorthwesternMed #GIST #SarcomaSmSurg #PrecisionOncology

Learned so much from Dr Jo Buyske @AmBdSurg about mission & governance with @CreightonSurg. 🙏 @wbalrefaie for invite & also an amazing 🏨 where caught up @joshuamammen & @JasonSicklick by the 🔥

The 14th Annual Department of Surgery Research Symposium brought together clinical, translational and engineering minds — all with a coastal backdrop. Dive into the highlights from an inspiring day of discovery. 🌊🥽 #UCSDSurgery #SurgicalScience #SurgicalInnovation

Yesterday, we held our 14th Annual #UCSDSurgery Research Symposium! The night included 101 presentations and a thoughtful talk on recent pediatrics research by David Hackam, MD, PhD. A huge thank you to all of our presenters and attendees!

🚨Hot off the press👉Pleased to share my new commentary: "Matching hallmarks of cancer complexity with N-of-1 precision oncology" 🧬 @MedCellPress 👉A viewpoint on the latest iteration of Doug Hanahan's Hallmarks of Cancer framework and @Dr_R_Kurzrock 's the i-PREDICT trial, and what they mean together for #precisionmedicine 👉What is #PrecisionOncology 's E=MC2 ? Tweetorial soon. @OncoAlert @MedwatchKate @OpenMedicineHQ @oncodaily @Aiims1742 @neerajaiims @weldeiry @chadinabhan Free @CellPressNews link for 50 days authors.elsevier.com/a/1mm2C…

Cancer treatment paradigms in the precision medicine era | Nature Medicine nature.com/articles/s41591-0…

Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Individually Dosed, Personalized Drug Combinations. Co-authored by @JasonSicklick & @Dr_R_Kurzrock. Read the full article. brnw.ch/21wZiC0

Listen to Patricia Thistlethwaite, MD, PhD, explain her team's publication on a new blood biomarker for idiopathic pulmonary arterial hypertension (IPAH). The study was published in @NatureMedicine on Jan. 9, 2026. Watch the interview: fox5sandiego.com/video/uc-sa…

Thanks. Such a pleasure to work with TargetCancer on the TRACK study, a one of a kind decentralized n-of-1 rare cancer trial built on the I-PREDICT model @VivekSubbiah